ESLA
Estrella Immunopharma, Inc.Healthcare · $17M market cap
Verdict
We can't put a fair value on ESLA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow ESLA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Nov 2, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Other filings
Questions about ESLA
Are insiders buying ESLA?
Since Nov 2, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar).
How can I check ESLA's value myself?
Use the free Sticker Price calculator, already filled with ESLA's numbers. Change the growth, P/E or required return and see what you'd pay. Open the calculator →
Similar stocks · Biotechnology
About Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of Nov 4, 2026. How the Payback Price works